ADVERTISEMENT

HER2-low breast cancer: review of new clinical developments

Miriam Davis, PhD   |   Clinical Summary   |   29 September 2022
ADVERTISEMENT

Takeaway

  • A new review article published in  JAMA Oncology  covers emerging developments around the approximately 50% of breast tumours that express low levels of the human epidermal growth factor receptor 2 (HER2), now called Erb-b2 receptor tyrosine kinase 2 (ERBB2).
  • A major milestone came in June 2022 with the Food and...

          

Topic Challenges

left
right